Latest Data Demonstrate Boehringer Ingelheim's Pramipexole (Mirapexin®/Sifrol®) Improves Broad Spectrum Of Symptoms Of Restless Legs Syndrome
In all studies presented, patients taking pramipexole rated clinically meaningful improvements to their night and day-time symptoms, as measured on the International Restless Legs Scale (IRLS). The IRLS measures several aspects of the condition, ranging from discomfort, the need to move around, and relief by moving around, to specific RLS symptoms such as sleep disturbance, day-time tiredness, mood disorder, as well as addressing overall severity, weekly frequency, daily severity, and impact on daily activities.1
"Patients with Restless Legs Syndrome need treatment that will help to improve all of their symptoms in the night and day-time. The new evidence presented today gives both clinicians and patients the confidence that pramipexole can be used to address the key aspects of this chronic condition," said Professor John W. Winkelman, MD, PhD, Medical Director of the Sleep Health Centre of Brigham and Women's Hospital, Boston, Massachusetts/USA and Harvard Medical School.
IRLS data were pooled from a total of 564 pramipexole recipients and 220 placebo recipients, all of whom had participated in one of three placebo-controlled double-blind randomised trials of pramipexole in RLS. Pramipexole improved symptoms across all IRLS subscores (range 0 to 4 points), versus placebo. The mean improvement in the pramipexole arm ranged from 0.9 points for 'impact on daily activities' and 1.0 for 'mood disturbance' to 1.8 points for 'need to move due to discomfort'.1 These results, confirmed by patients themselves, reinforce the overall benefits of pramipexole.
Broad range of patients
According to another study presented today at MDS, RLS patients with concomitant diseases, or who are taking additional therapies, benefited from treatment with pramipexole.2 It is very common for RLS patients to suffer from additional conditions, including seasonal allergy, hypertension and gastroesophageal reflux.2 Furthermore, patients frequently take medication for other conditions, including analgesics, anti-inflammatory and anti-rheumatic drugs, and agents affecting cardiovascular function.2
Results from a 12-week randomised, double-blind, placebo-controlled trial show that even with the high frequencies of concomitant diagnoses and therapies, pramipexole was associated with a significant 12-week reduction of IRLS by an adjusted mean of -13.5, compared with -9.3 for placebo (P
Ultimele date demonstra lui Pramipexole Boehringer Ingelheim (Mirapexin ? / ? Sifrol) îmbunãtãþeºte spectru larg de simptome de sindrom de picioare nelinistit - Latest Data Demonstrate Boehringer Ingelheim's Pramipexole (Mirapexin®/Sifrol®) Improves Broad Spectrum Of Symptoms Of Restless Legs Syndrome - articole medicale engleza - startsanatate